Renata PLC, a leading local pharmaceutical company, launched 13 new products in the highly-regulated markets of Europe, Australia, Canada, and the UK in 2024.

The launches are a testament to Renata's vision of developing world-class, high-quality medication and becoming a revered pharmaceutical company on a global scale, the pharmaceutical manufacturer said in a statement today.

The company has shipped Amantadine capsules, along with tablets named Colchicine, Carbimazole, and Propylthiouracil to the UK, which will be commercialized under Renata's branding, according to the statement.

Of these, Amantadine and Propylthiouracil have already been launched, according to the statement.

Additionally, Renata has also recently shipped Clindamycin, an essential antibiotic for treating serious bacterial infections, to the UK market.

The company has introduced a new strength of an existing product, Hydrocortisone 5 mg, in Ireland, addressing therapeutic needs in endocrinology and inflammation management.

Further bolstering its presence in regulated markets, Renata has secured pivotal approvals for multiple products in key territories.

It has secured its first approval in Canada with Desogestrel + Ethinylestradiol 0.15/0.03 mg, an oral contraceptive pill.

Renata's approval for Amantadine capsules in Denmark, Sweden, and Norway is expected to expand access to Parkinson's treatments in Nordic markets.

Moreover, Renata's recent approval in Australia for Rivaroxaban, used in thrombosis prevention, in an innovative capsule dosage form, adds to its growing portfolio of generics in this key market, where Renata secured its first approval not too long ago.

Similarly, Renata is poised to introduce innovative therapies in both existing and new markets with a series of upcoming launches.

It will soon ship its first approved product in France, Cabergoline 0.5 mg.

Leveraging Renata's pan-European approval for this product, Cabergoline 0.5 mg is also set to be shipped to Denmark and other Nordic countries.

Additionally, preparations for the shipment of Rivaroxaban tablets, an anticoagulant critical in thrombosis prevention, are currently underway for the UK.

This product will also be commercialised under Renata's branding, further establishing the company as a reliable pharmaceutical brand in one of the world's most regulated pharmaceutical landscapes.

"These global milestones have been possible due to Renata's commitment to compliance with stringent regulatory frameworks, robust state-of-the-art manufacturing facilities, and partnerships with global distributors, ensuring reliable supply chains and patient-centric delivery," the company said in the statement.